HC Wainwright & Co. has initiated coverage on BioMarin Pharmaceutical Inc (BMRN) with a Neutral rating as of September 7, 2025. This marks the firm's first assessment of the biotechnology company, which specializes in therapies for rare diseases.
BioMarin, headquartered in San Rafael, California, has a market cap of $10.3 billion and reported a P/E ratio of 19.73 with an EPS of 2.64. The company offers eight commercial therapies, including Vimizim and Roctavian, and has a robust pipeline of clinical programs.
The upcoming earnings report is scheduled for August 3, 2026, with an estimated EPS of $1.17 and revenue expectations of $854.8 million. Analyst ratings can provide valuable insights but should be considered alongside other factors such as company fundamentals and market conditions.
The move underscores the firm's initial evaluation amidst BioMarin's ongoing developments in the biotechnology space. As of November 1, 2025, the analyst consensus for BioMarin stands at 12 Strong Buy, 16 Buy, and 6 Hold ratings, reflecting varied opinions on the company's market potential.